The predictive value of CSF multiple assay in multiple sclerosis: A single center experience

被引:16
|
作者
De Fino, C. [1 ]
Lucchini, M. [1 ]
Lucchetti, D. [2 ]
Nociti, V [1 ]
Losavio, F. A. [1 ]
Bianco, A. [1 ]
Colella, F. [2 ]
Ricciardi-Tenore, C. [2 ]
Sgambato, A. [2 ]
Mirabella, M. [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Inst Neurol, Fdn Policlin Univ A Gemelli IRCCS, Largo A Gemelli 8, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Inst Gen Pathol, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
关键词
Multiple Sclerosis; CHI3L1; sCD163; Osteopontin; BAFF; CHITINASE; 3-LIKE; CEREBROSPINAL-FLUID; OSTEOPONTIN; DISABILITY; BIOMARKER; BAFF;
D O I
10.1016/j.msard.2019.07.030
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory, neurodegenerative disorder. Many studies are investigating the potential role of body fluid biomarkers as prognostic factors for early identification of patients presenting with clinical isolated syndrome (CIS) at high risk for conversion to MS or to recognize RRMS patients at high risk for progression. Objectives: To evaluate the correlation between levels of BAFF, chitinase 3-like 1 (CHI3L1), sCD163, Osteopontin (OPN), both on serum and cerebral spinal fluid (CSF), and the disease activity and progression. We also want to explore a possible relationship between serological and CSF biomarker's levels. Patients and methods: We enrolled 82 patients between June 2014 and June 2016. Seventy-one received a diagnosis of demyelinating disease of CNS (46 RRMS and 25 CIS), while 11 were affected by other neurological diseases. All patients underwent a neural axis MRI, lumbar puncture and blood samples. Levels of BAFF, CHI3L1, sCD163, OPN on serum and CSF were analyzed by Luminex xMAP system, with a kit 11-plex ad hoc. Results: The CSF CHI3L1, sCD163 and OPN levels were significantly higher in MS patients than in controls. We did not find significant differences in serum CHI3L1, sCD163 and OPN levels, nor CSF or serum BAFF levels between patient and control groups. We found significantly higher CSF level of sCD163 and CHI3L1 in all patients' subgroups compared with controls, while OPN was higher in CIS and RR subgroups. We did not find significant differences for serum and CSF levels of all the markers between patients with or without clinical or radiological disease activity. CSF sCD163 and CHI3L1 levels was significant higher in CIS patients who converted to MS (p < 0.05). Using ROC curve analysis, CSF sCD163 resulted the best predictive factor. CSF CHI3L1 and OPN levels resulted useful independent predictors too. Combined ROCS of those three analytes demonstrated a better predictive value, with sCD163 and CHI3L1 resulting as the best combination. Conclusions: CSF sCD163 CHI3L1 and OPN levels were higher in MS patients whereas serum CHI3L1, sCD163 and OPN levels did not show differences compared with controls. This finding confirms the high CSF specificity with regards to the analysis of processes, inflammatory and non-inflammatory, that occur within the CNS.
引用
收藏
页码:176 / 181
页数:6
相关论文
共 50 条
  • [1] THE PREDICTIVE VALUE OF CSF ELECTROPHORESIS IN POSSIBLE MULTIPLE-SCLEROSIS
    MOULIN, D
    PATY, D
    EBERS, G
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1981, 8 (02) : 189 - 189
  • [2] Multiple Sclerosis in Childhood: Single Center Experience
    Bodur, Muhittin
    Toker, Rabia Tutuncu
    Okan, Mehmet Sait
    GUNCEL PEDIATRI-JOURNAL OF CURRENT PEDIATRICS, 2021, 19 (02): : 225 - 230
  • [3] Pediatric Onset Multiple Sclerosis: A Single Center Experience
    Yamamoto, E.
    Ginsberg, M.
    Rensel, M.
    Moodley, M.
    ANNALS OF NEUROLOGY, 2016, 80 : S332 - S332
  • [4] Ocrelizumab in patients with multiple sclerosis: a single center experience
    Brady, C.
    Lakhani, D.
    Hou, B.
    Carpenter, J.
    Luo, W.
    Magda, S.
    Haxton, R.
    Tripathi, R.
    Deib, G.
    Sriwastava, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 176 - 177
  • [5] Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center
    Alldredge, Brett
    Jordan, Allison
    Imitola, Jaime
    Racke, Michael K.
    CLINICAL NEUROPHARMACOLOGY, 2018, 41 (02) : 56 - 59
  • [6] Coexistence of epilepsy or seizure and multiple sclerosis; a single center experience
    Saridas, Furkan
    Mesut, Gizem
    Ozpar, Rifat
    Koc, Emine Rabia
    Hakyemez, Bahattin
    Demir, Aylin Bican
    Turan, Omer Faruk
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 92
  • [7] Rituximab treatment in multiple sclerosis patients: experience of a single center
    Mulero, P.
    Pappolla, A.
    Campra, M.
    Tagliani, P.
    Robles, M. A.
    Vidal-Jordana, A.
    Arrambide, G.
    Rio, J.
    Comabella, M.
    Castillo, J.
    Galan, I.
    Rodriguez-Acevedo, B.
    Midaglia, L.
    Sastre-Garriga, J.
    Tintore, M.
    Montalban, X.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 677 - 677
  • [8] Mitoxantrone in the Treatment of Multiple Sclerosis: a Single-Center Experience
    Taskapilioglu, Ozlem
    Sener, Deniz Kamaci
    Turan, Asli Bahar
    Yurtogullari, Sukran
    Tutuncu, Ahmet
    Gullulu, Sumeyye
    Ocakoglu, Gokhan
    Turan, Omer Faruk
    TURKISH JOURNAL OF NEUROLOGY, 2012, 18 (02) : 62 - 66
  • [9] Efficacy and safety of cyclophosphamide in progressive multiple sclerosis: a single center experience
    Yamout, B. I.
    Zeineddine, M. M.
    Ghassan, S. A.
    Ayoubi, N. K.
    Taha, A. J.
    Massouh, J. R.
    Tamim, H.
    Khoury, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 804 - 805
  • [10] Beta-interferons in multiple sclerosis: A single center experience in India
    Gupta, Salil
    Varadarajulu, R.
    Ganjoo, R. K.
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2010, 13 (02) : 132 - 135